

phone: 877-230-7555

**TTY:** 711

prevea360.com

August 5, 2021

Dear Prevea360 Health Plan Provider:

Thank you for your continued dedication and commitment to providing high-quality care to our members during the public health emergency.

This notification contains information regarding:

- In-home COVID-19 vaccine administration.
- COVID-19 monoclonal antibody therapies updates.

Information in this notification applies to the following Prevea360 Health Plan products: Commercial (fully insured, including ACA), Dean Administrative Services Only (ASO), and Medicare Advantage.

## **In-Home COVID-19 Vaccine Administration**

Centers for Medicare & Medicaid Services (CMS) has established a new HCPCS code for inhome COVID-19 vaccine administration:

 M0201 - COVID-19 vaccine administration inside a patient's home; reported only once per individual home per date of service when only COVID-19 vaccine administration is performed at the patient's home.

For dates of service on and after June 8, 2021, providers receive additional reimbursement for in-home COVID-19 vaccine administration billed with place of service code "12- Home." Prevea360 Health Plan will update fee schedules for in-home COVID-19 vaccine administration as appropriate to specific provider agreements.

Providers should submit claims for in-home vaccine administration to Prevea360 Health Plan, except for Medicare Advantage claims which must be submitted directly to CMS. Refer to CMS guidance for Medicare Billing for COVID-19 Vaccine Shot Administration.

### **Monoclonal Antibody Therapy Updates**

Prevea360 Health Plan continues to monitor monoclonal antibody therapy updates. As of the date of this notice, the following investigational monoclonal antibody therapies are under Food and Drug Administration (FDA) emergency use authorization (EUA):

- Casirivimab and Imdevimab, administered together. See our <u>COVID-19 Communication:</u> 5/25/21.
- Bamlanivimab and Etesevimab, administered together. (*Note*: The Federal Government is pausing distribution until further notice.)
- Sotrovimab Effective with <u>EUA</u> on May 26, 2021. <u>HCPCS codes</u> are available for the product and administration in a healthcare setting or home.
- Tocilizumab Effective with EUA on June 24, 2021. HCPCS codes are available for the

product and administration in an inpatient setting only.

- Because of the limited clinical situations allowed under EAU, claims for Tocilizumab should be billed on a 12x Type of Bill.
- The EUA for tocilizumab also allows for two infusions to the same patient in limited situations when clinically necessary.

Unlike the other monoclonal antibody therapies, the federal government is not furnishing Sotrovimab or Tocilizumab products for free. Providers may purchase the products through their standard channels.

#### Member Cost Share

Member cost share continues to be waived for monoclonal antibody therapies under EUA.

#### Claims

Claims for the Sotrovimab and Tocilizumab administration **and** product should be submitted to Prevea360 Health Plan, except for Medicare Advantage claims.

### Medicare Advantage

Medicare Advantage claims for COVID-19 monoclonal antibody therapies should be submitted directly to CMS. CMS will not reimburse for the COVID-19 monoclonal antibody products that providers receive for free. When COVID-19 monoclonal antibody doses are provided by the government without charge, providers should only bill for the administration.

Please refer to the CMS <u>Monoclonal Antibody COVID-19 Infusion web page</u> regularly for the most current EUA, medical documentation, coding, billing, and payment information.

# <u>Additional Health Plan Information</u>

For additional health plan information and previous provider communications, refer our <u>COVID-19 provider information web page</u> located at the top of all <u>Prevea360.com</u> web pages. Providers are encouraged to check our website regularly for new and updated information

Please contact your assigned Provider Network Consultant with any questions.

Thank you again for your commitment to our members.

Sincerely,

Loretta A. Lorenzen

Vice President- Network Management & Contracting